Related Experiment Video
Updated: Jan 24, 2026

Assessing Insulin Clearance in Mice via In Situ Liver Perfusion
Published on: December 13, 2024
Insulin Aspart-szjj: An Insulin Aspart Biosimilar
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.
None:
Insulin aspart-szjj (MERILOG™) is a biosimilar of the reference rapid-acting insulin analog, insulin aspart, and is approved for the same indication as reference insulin aspart: to improve glycemic control in adult and pediatric patients with diabetes mellitus. The physicochemical characteristics of insulin aspart-szjj were similar to reference insulin aspart, and the pharmacodynamic and pharmacokinetic equivalence of the agents has been shown in patients with type 1 diabetes. Insulin aspart-szjj demonstrated clinical efficacy similar to that of reference insulin aspart in patients with type 1 or type 2 diabetes and was generally well tolerated in this population. The tolerability, safety, and immunogenicity profiles of insulin aspart-szjj were similar to those of reference insulin aspart. The role of insulin aspart in the management of diabetes mellitus is well established, and insulin aspart-szjj provides an effective biosimilar alternative for patients with diabetes mellitus requiring reference insulin aspart.
Related Concept Videos
Insulin Secretory Vesicles
Insulin: The Receptor and Signaling Pathways
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...

